This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Lucrative Bets Boasting High Earnings Yield
by Rimmi Singhi
TotalEnergies SE (TTE), Nutrien (NTR), FedEx (FDX) and Pfizer (PFE) could be some attractive bets if you are looking for high earnings yield picks.
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
by Zacks Equity Research
AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
by Zacks Equity Research
Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt
by Zacks Equity Research
Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.
Exelixis (EXEL) Amends Agreement With Iconic Therapeutics
by Zacks Equity Research
Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.
Lilly (LLY) Inks Deal for Multiple Neurologic Indications
by Zacks Equity Research
Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.
Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug
by Kinjel Shah
FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.
Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc
by Zacks Equity Research
AbbVie, Inc. and Pfizer Inc are highlighted in this investment idea article.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $54.84, marking a -1.42% move from the previous day.
Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.
How to Select Stocks During Volatile Market Periods
by Bryan Hayes
How to Select Stocks During Volatile Market Periods
4 Reasons Why You Should Add AbbVie (ABBV) to Your Portfolio
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.
Company News for Jan 6, 2022
by Zacks Equity Research
Companies In The News Are: PFE, LULU, NKE, T, VZ.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
5 Small-Cap ETFs to Profit From the January Effect
by Sweta Killa
After registering double-digit annual growth, Wall Street is poised to gain from the historical trend of January Effect.
Best Growth Stocks to Buy for January 5th
by Zacks Equity Research
ABG, APO, and PFE made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 5, 2022
AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug
by Zacks Equity Research
AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
The Zacks Analyst Blog Highlights: Meta Platforms, Inc., Bank of America Corporation, Mastercard Inc., Pfizer Inc. and Medtronic plc
by Zacks Equity Research
Meta Platforms, Inc., Bank of America Corporation and Mastercard Inc., Pfizer Inc. and Medtronic plc are highlighted in this analyst blog.
Top Stock Reports for Meta Platforms, Bank of America & Mastercard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (FB), Bank of America Corporation (BAC), and Mastercard Incorporated (MA).
Here's Why Momentum Investors Will Love Pfizer (PFE)
by Zacks Equity Research
Does Pfizer (PFE) have what it takes to be a top stock pick for momentum investors? Let's find out.
PFE vs. RHHBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. RHHBY: Which Stock Is the Better Value Option?
Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.
New Strong Buy Stocks for January 4th
by Zacks Equity Research
ABG, CNTY, IIJIY, ORAN, and PFE have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2022.